expand/collapse risk warning

CFDs come with a high risk of losing money rapidly due to leverage. 71% of accounts lose money when trading CFDs with this provider. You should understand how CFDs work and consider if you can take the risk of losing your money.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

71% of retail investor accounts lose money when trading CFDs with this provider.


Trade [[data.name]]

[[ data.name ]]

[[ data.ticker ]]

[[ data.price ]] [[ data.change ]] ([[ data.changePercent ]]%)

Low: [[ data.low ]]

High: [[ data.high ]]







EVOTEC is a German biotech company located in the city of Hamburg. Since 1993, EVOTEC has been working to test and develop treatments across a host of therapeutic areas, namely neurological conditions, metabolic diseases, cancers and infectious diseases.

As of October 2009, EVOTEC was formally entered into the TecDAX index, monitoring the performance of Germany’s top 30 corporations within its tech industry. As of November 2021, EVOTEC also formalised a secondary listing of its shares on the US-based US100 stock exchange.

As of 2021, EVOTEC posted annual revenues totalling €618m, with an employee base of more than 4,200. Since the turn of the millennium, EVOTEC has embarked on a series of high-profile acquisitions to bolster its in-house expertise. This includes buyouts of biotech brands such as Euprotec, Aptuit, Just Biologics and Rigenerand.

The EVOTEC share price has fluctuated significantly since its initial public offering (IPO). It reached an all-time-high value of €92.50 in March 2000, before plunging fast to just €5.50 in September 2001. The price of EVOTEC shares largely flatlined for the remainder of the decade and into the 2010s and the post-recessionary environment.

In fact, it wasn’t until early 2017 that the EVOTEC share price would begin to gain traction once again, rising to €21.13 in October of that year. This spike coincided with the company’s acquisition of drug development services provider Aptuit in a deal worth €256m.

As the Covid-19 pandemic struck, biotech stocks like EVOTEC enjoyed greater exposure, resulting in its share price peaking at €45.07 in early October 2021. It has since lost most of those gains and in 2022 the EVOTEC share price was down a touch over 61%.

There are multiple competitors in the biotech and drug development field for EVOTEC. BioNTech is arguably the biggest player in the biotech and drug development space, with a valuation of more than $37bn. BioNTech is also headquartered in Germany (Mainz).

Life sciences giant Eurofins is arguably the longest-standing firm in this field, established in 1987. This firm has locations spanning all four corners of the globe, with an employee base of almost 58,000 dwarfing that of EVOTEC.

Research-based biopharmaceutical company, AstraZeneca, is another major player in EVOTEC’s field. The Cambridge-headquartered company has played a key role in the development of medicines and treatments across a string of therapy areas, including respiratory diseases like Covid-19.

Swap long [[ data.swapLong ]] points
Swap short [[ data.swapShort ]] points
Spread min [[ data.stats.minSpread ]]
Spread avg [[ data.stats.avgSpread ]]
Min contract size [[ data.minVolume ]]
Min step size [[ data.stepVolume ]]
Commission and Swap Commission and Swap
Leverage Leverage
Trading Hours Trading Hours

* The spreads provided are a reflection of the time-weighted average. Though Skilling attempts to provide competitive spreads during all trading hours, clients should note that these may vary and are susceptible to underlying market conditions. The above is provided for indicative purposes only. Clients are advised to check important news announcements on our Economic Calendar, which may result in the widening of spreads, amongst other instances.

The above spreads are applicable under normal trading conditions. Skilling has the right to amend the above spreads according to market conditions as per the 'Terms and Conditions'.

Trade [[data.name]] with Skilling

All Hassle-free, with flexible trade sizes and with zero commissions!*

  • Trade 24/5
  • Minimum margin requirements
  • No commission, only spread
  • Fractional shares available
  • Easy to use platform

*Other fees may apply.

Sign up

Why Trade [[data.name]]

Make the most of price fluctuations - no matter what direction the price swings and without capital restrictions that come with buying the underlying asset.


Capitalise on rising prices (go long)


Capitalise on falling prices (go short)


Trade with leverage
Hold larger positions than the cash you have at your disposal


Trade on volatility
No need to own the asset


No commissions
Just low spreads


Manage risk with in-platform tools
Ability to set take profit and stop loss levels